Ironically, I had just finished reading this in an e-mail that MSIF mailer sent to me yesterday.
I know that some people think that I make up a lot of the comments that I write about Tysabri on the net. This paper is one example of MS docs who have a different opinion on how Tysabri should be introduced into large scale use. I'm sure that Biogen/Elan would have something to say about these fellows' opinions. Would also be interesting to see if these docs had any affiliation with the competitor drug companies.